Determination of appropriate study endpoints is the backbone of any drug development program. Cardiovascular clinical research requires a precise approach to ensuring that study targets are met.

TORONTO (PRWEB)
July 19, 2021

In cardiovascular trials, surrogate biomarkers often appear in different regalia, as clinical endpoints, for eligibility criteria and/or for safety monitoring. On the one hand, cardiac biomarkers may be used to help precisely carve out the right study population with surgical precision. On the other hand, biomarkers, if used inappropriately, may bluntly and inefficiently whittle the trial population and objectives.

Determination of appropriate study endpoints is the backbone of any drug development program. Cardiovascular clinical research requires a precise approach to ensuring that study targets are met. Thus, carefully planned applications of each biomarker must be clearly outlined at the start of development and should be used in conjunction with functional and quality of life endpoints to measure safety and efficacy of new therapeutic options.

Selecting appropriate biomarkers and thresholds for patient eligibility and patient safety monitoring throughout the course of a clinical trial can improve the efficiency of the study, duration of study enrolment and enhance selection of the most appropriate trial population. Cardiac biomarkers, when used in conjunction with standard safety assessments can help to pinpoint safety concerns or identify markers of trial success.

Join leading expert in cardiovascular biomarkers James Januzzi, Hutter Family Professor of Medicine, Harvard Medical School, along with experts from Medpace, Richard Lee, Senior Medical Director, Medical Department; Liz Moore, Advanced Clinical Practitioner Manager; and Kelly Millhaem, Senior Clinical Trial Manager, for the live webinar on Wednesday, August 4, 2021 at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Discussion with Dr. James Januzzi, MD.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email: